{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:07:43Z","timestamp":1770412063328,"version":"3.49.0"},"publisher-location":"Chichester, UK","reference-count":105,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd000296.pub2","type":"reference-entry","created":{"date-parts":[[2005,10,7]],"date-time":"2005-10-07T11:54:39Z","timestamp":1128686079000},"source":"Crossref","is-referenced-by-count":31,"title":["Budesonide for induction of remission in Crohn's disease"],"prefix":"10.1002","author":[{"given":"A","family":"Otley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AH","family":"Steinhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,19]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group","volume":"115","author":"Bar-Meir","year":"1998","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00042737-200401000-00008","article-title":"Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial","volume":"16","author":"Escher","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"13","key":"10.1002\/14651858.CD000296.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1002\/14651858.CD000296.pub2-BIB5|cit5","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"13","key":"10.1002\/14651858.CD000296.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1002\/14651858.CD000296.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","article-title":"Budesonide CIR capsules (one or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States","volume":"97","author":"Tremaine","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB9|cit9","first-page":"A771","volume":"108","author":"Andus","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/dtb.1997.35430","article-title":"Controlled-release budesonide in Crohn's disease","volume":"35","author":"Anonymous","year":"1997","journal-title":"Drug Ther Bull"},{"issue":"9 Suppl Auf Dem","key":"10.1002\/14651858.CD000296.pub2-BIB11|cit11","first-page":"1","article-title":"[Budesonide: effective, with low side effects. On the road to new treatment methods in Crohn disease]","volume":"39","author":"Anonymous","year":"1998","journal-title":"Internist (Berl)"},{"issue":"23","key":"10.1002\/14651858.CD000296.pub2-BIB12|cit12","first-page":"43","article-title":"[Steroids in Crohn disease. Side-effects can be minimized]","volume":"143","author":"Anonymous","year":"2001","journal-title":"MMW Fortschr Med"},{"issue":"1122","key":"10.1002\/14651858.CD000296.pub2-BIB13|cit13","first-page":"6","article-title":"Budesonide (Entocort EC) for Crohn's disease","volume":"44","author":"Anonymous","year":"2002","journal-title":"Med Lett Drugs Ther"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3109\/07853899509019248","article-title":"Budesonide or prednisolone in active Crohn's disease","volume":"27","author":"Baert","year":"1995","journal-title":"Ann Med"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB15|cit15","first-page":"153","article-title":"Corticosteroid treatment in active Crohn's disease","volume":"61","author":"Belaiche","year":"1998","journal-title":"Acta Gastroenterol Belg"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB16|cit16","first-page":"508","article-title":"Current treatment modalities in active Crohn's disease","volume":"31","author":"Biancone","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJM199808063390610","article-title":"Treatment of Crohn's disease at the turn of the century","volume":"339","author":"Bickston","year":"1998","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1002\/14651858.CD000296.pub2-BIB18|cit18","first-page":"4","article-title":"Coping with Crohn's disease","volume":"4","author":"Bickston","year":"1998","journal-title":"Health News"},{"issue":"11","key":"10.1002\/14651858.CD000296.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/bjs.1800841104","article-title":"Preventing postoperative recurrence of Crohn's disease","volume":"84","author":"Borley","year":"1997","journal-title":"Br J Surg"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB20|cit20","first-page":"226","article-title":"The case against routine post-operative therapy for prevention of recurrence in Crohn's disease","volume":"30","author":"Breslin","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"5","key":"10.1002\/14651858.CD000296.pub2-BIB21|cit21","first-page":"247","article-title":"Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group","volume":"33","author":"Caesar","year":"1995","journal-title":"Z Gastroenterol"},{"issue":"14","key":"10.1002\/14651858.CD000296.pub2-BIB22|cit22","first-page":"445","article-title":"Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group","volume":"44","author":"Caesar","year":"1997","journal-title":"Hepatogastroenterology"},{"key":"10.1002\/14651858.CD000296.pub2-BIB23|cit23","first-page":"III43","article-title":"New steroids and new salicylates in inflammatory bowel disease: a critical appraisal","volume":"50 Suppl 3","author":"Campieri","year":"2002","journal-title":"Gut"},{"issue":"12","key":"10.1002\/14651858.CD000296.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1111\/j.1572-0241.2000.03367.x","article-title":"Increased levels of homocysteine in patients with Crohn's disease are related to folate levels","volume":"95","author":"Chowers","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1572-0241.2002.05609.x","article-title":"Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy","volume":"97","author":"Cino","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.48.2.186","article-title":"Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease","volume":"48","author":"Cortot","year":"2001","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD000296.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2036.1998.00321.x","article-title":"Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease","volume":"12","author":"D'Haens","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1002\/14651858.CD000296.pub2-BIB28|cit28","first-page":"802","article-title":"[Advances in the topical steroid treatment of inflammatory bowel diseases]","volume":"87","author":"Diaz Blasco","year":"1995","journal-title":"Rev Esp Enferm Dig"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00042737-199903000-00011","article-title":"Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group","volume":"11","author":"Ewe","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","article-title":"Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group","volume":"12","author":"Ferguson","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1002\/14651858.CD000296.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s001080050127","article-title":"[Topical steroids in chronic inflammatory bowel diseases]","volume":"38","author":"Fleig","year":"1997","journal-title":"Internist (Berl)"},{"key":"10.1002\/14651858.CD000296.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF03042029","article-title":"[Clinical effects of 5-aminosalicylic acid preparations in Crohn disease]","volume":"94 Suppl 1","author":"Fleig","year":"1999","journal-title":"Med Klin (Munich)"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1440-1681.2000.03238.x","article-title":"Treatment of joint pain in Crohn's patients with budesonide controlled ileal release","volume":"27","author":"Florin","year":"2000","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"12","key":"10.1002\/14651858.CD000296.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00042737-200112000-00006","article-title":"Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease","volume":"13","author":"Gelbmann","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1002\/14651858.CD000296.pub2-BIB35|cit35","first-page":"373","article-title":"Therapeutic strategies for pediatric Crohn disease","volume":"19","author":"Grand","year":"1996","journal-title":"Clin Invest Med"},{"issue":"9","key":"10.1002\/14651858.CD000296.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1046\/j.1365-2036.2001.01055.x","article-title":"Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules","volume":"15","author":"Green","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD000296.pub2-BIB38|cit38","first-page":"757","article-title":"[Crohn disease: prevention and drug therapy]","volume":"66","author":"Gross","year":"1995","journal-title":"Chirurg"},{"key":"10.1002\/14651858.CD000296.pub2-BIB39|cit39","unstructured":"Gross V Caesar I Andus T Vogelsang H Adler G Malchow H Gastroenterology 1997 A1098"},{"key":"10.1002\/14651858.CD000296.pub2-BIB40|cit40","unstructured":"Gross V Caesar I Andus T Vogelsang H Adler G Malchow H Gastroenterology 1997 A495"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/gut.42.4.493","article-title":"Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group","volume":"42","author":"Gross","year":"1998","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0016-5085(99)70125-3","article-title":"Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group","volume":"116","author":"Hellers","year":"1999","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00054725-200008000-00004","article-title":"Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group","volume":"6","author":"Irvine","year":"2000","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00005176-200107000-00013","article-title":"Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth","volume":"33","author":"Kundhal","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"51","key":"10.1002\/14651858.CD000296.pub2-BIB45|cit45","first-page":"2533","article-title":"[Locally acting glucocorticoids in chronic intestinal inflammation]","volume":"138","author":"Lamers","year":"1994","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0950-3528(98)90092-6","article-title":"Adjuvant post-operative therapy","volume":"12","author":"Leiper","year":"1998","journal-title":"Baillieres Clin Gastroenterol"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/088307380101600617","article-title":"Benign intracranial hypertension associated with budesonide treatment in children with Crohn's disease","volume":"16","author":"Levine","year":"2001","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1067\/mpd.2002.119992","volume":"140","author":"Levine","year":"2002","journal-title":"J Pediatr"},{"key":"10.1002\/14651858.CD000296.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/ibd.3780070506","article-title":"Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease","volume":"7 Suppl 1","author":"Lichtenstein","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1002\/14651858.CD000296.pub2-BIB50|cit50","unstructured":"Lofberg R Danielsson A Salde L Gastroenterology 1991 A226"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2036.1993.tb00141.x","volume":"7","author":"Lofberg","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study","volume":"39","author":"Lofberg","year":"1996","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD000296.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0016-5085(99)70034-X","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease","volume":"116","author":"Lowry","year":"1999","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2036.2001.00910.x","article-title":"Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease","volume":"15","author":"Lundin","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1002\/14651858.CD000296.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00008480-199810000-00009","article-title":"Ongoing advances in inflammatory bowel diseases, including maintenance therapies, biologic agents, and biology of disease","volume":"10","author":"Mack","year":"1998","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s002619900163","article-title":"Magnetic resonance imaging of Crohn disease: early recognition of treatment response and relapse","volume":"22","author":"Madsen","year":"1997","journal-title":"Abdom Imaging"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB57|cit57","first-page":"459","article-title":"[Budesonide in acute attacks of Crohn disease of medium intensity]","volume":"19","author":"Marteau","year":"1995","journal-title":"Gastroenterol Clin Biol"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB58|cit58","first-page":"406","article-title":"[Current medical therapies for Crohn's disease in Japan]","volume":"98","author":"Munakata","year":"1997","journal-title":"Nippon Geka Gakkai Zasshi"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/j.1572-0241.2001.03917.x","article-title":"A successful switch from prednisone to budesonide for neuropsychiatric adverse effects in a patient with ileal Crohn's disease","volume":"96","author":"Nahon","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD000296.pub2-BIB60|cit60","unstructured":"Novacek G Kleinberger M Vogelsang H Moser G Lochs H Gastroenterology 1994 A746"},{"issue":"5","key":"10.1002\/14651858.CD000296.pub2-BIB61|cit61","first-page":"251","article-title":"Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study","volume":"33","author":"Novacek","year":"1995","journal-title":"Z Gastroenterol"},{"issue":"10","key":"10.1002\/14651858.CD000296.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2007-1023950","article-title":"[Pyostomatitis vegetans and Crohn's disease. A specific association of 2 diseases]","volume":"123","author":"Oettinger","year":"1998","journal-title":"Dtsch Med Wochenschr"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1155\/2001\/490921","article-title":"Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada","volume":"15","author":"Panaccione","year":"2001","journal-title":"Can J Gastroenterol"},{"issue":"11","key":"10.1002\/14651858.CD000296.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.2000.00867.x","article-title":"Budesonide in the treatment of Crohn's disease: a meta-analysis","volume":"14","author":"Papi","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1002\/14651858.CD000296.pub2-BIB65|cit65","first-page":"943","article-title":"[New therapeutic modalities in Crohn's disease]","volume":"136","author":"Rachmilewitz","year":"1999","journal-title":"Harefuah"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00005176-199703000-00020","article-title":"Severe hypokalemia after budesonide treatment for Crohn's disease","volume":"24","author":"Rosenbach","year":"1997","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1002\/14651858.CD000296.pub2-BIB67|cit67","unstructured":"Roth M Ueberschaer B Ewe K Gross V Scholmerich J Gastroenterology 1992 A688"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB68|cit68","first-page":"968","article-title":"Treatment of active Crohn's disease with an oral slow-release budesonide formulation","volume":"88","author":"Roth","year":"1993","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/09629359891036","article-title":"The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease","volume":"7","author":"Rutgeerts","year":"1998","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB70|cit70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/gut.45.1.13","article-title":"Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease","volume":"45","author":"Rutgeerts","year":"1999","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000296.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/ibd.3780070503","article-title":"Conventional treatment of Crohn's disease: objectives and outcomes","volume":"7 Suppl 1","author":"Rutgeerts","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB72|cit72","doi-asserted-by":"crossref","first-page":"60-61; discussi","DOI":"10.1097\/00054725-200102000-00010","article-title":"The use of budesonide in the treatment of active Crohn's disease is good clinical practice","volume":"7","author":"Rutgeerts","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"13","key":"10.1002\/14651858.CD000296.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJM199409293311311","article-title":"Budesonide for inflammatory bowel disease. It is a magic bullet?","volume":"331","author":"Sachar","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD000296.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"17C","DOI":"10.1155\/2000\/513130","article-title":"Steroid-dependent Crohn's disease","volume":"14 Suppl C","author":"Sandborn","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"10.1002\/14651858.CD000296.pub2-BIB75|cit75","first-page":"30","article-title":"[Clinical effectiveness of various budesonide preparations in Crohn disease]","volume":"94 Suppl 1","author":"Scholmerich","year":"1999","journal-title":"Med Klin (Munich)"},{"issue":"7","key":"10.1002\/14651858.CD000296.pub2-BIB76|cit76","first-page":"222","article-title":"[Drug treatment of chronic inflammatory bowel diseases: current status and prospects]","volume":"130","author":"Seibold","year":"2000","journal-title":"Schweiz Med Wochenschr"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB77|cit77","first-page":"15","article-title":"[Recent advances in treatment of Crohn's disease]","volume":"99","author":"Shimizu","year":"2002","journal-title":"Nippon Shokakibyo Gakkai Zasshi"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB78|cit78","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002913","article-title":"Budesonide for maintenance of remission in Crohn's disease","author":"Simms","year":"2001","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD000296.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2165\/00003495-199550050-00006","article-title":"Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease","volume":"50","author":"Spencer","year":"1995","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD000296.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF03042032","article-title":"[Consequences of galenic differences and outcome of clinical trials with budesonide and 5-aminosalicylic acids for therapy of Crohn disease]","volume":"94 Suppl 1","author":"Stange","year":"1999","journal-title":"Med Klin (Munich)"},{"key":"10.1002\/14651858.CD000296.pub2-BIB81|cit81","doi-asserted-by":"crossref","first-page":"23C","DOI":"10.1155\/2000\/480782","article-title":"Maintenance therapy in Crohn's disease","volume":"14 Suppl C","author":"Steinhart","year":"2000","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB82|cit82","article-title":"Corticosteroids for maintenance of remission in Crohn's disease","author":"Steinhart","year":"2003","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/gast.2002.34225","volume":"123","author":"Steinhart","year":"2002","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB84|cit84","doi-asserted-by":"crossref","first-page":"321-8; discussi","DOI":"10.1097\/00054725-200011000-00009","article-title":"Prevention of relapse of Crohn's disease","volume":"6","author":"Sutherland","year":"2000","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB85|cit85","doi-asserted-by":"crossref","first-page":"58-59; discussi","DOI":"10.1097\/00054725-200102000-00009","article-title":"Budesonide: is no evidence of a difference the same as evidence of no difference?","volume":"7","author":"Sutherland","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1002\/14651858.CD000296.pub2-BIB86|cit86","doi-asserted-by":"crossref","first-page":"560","DOI":"10.5694\/j.1326-5377.1998.tb123415.x","article-title":"Budesonide substitution in Crohn's disease relieves CNS toxicity of systemic steroids","volume":"169","author":"Thomas","year":"1998","journal-title":"Med J Aust"},{"issue":"23","key":"10.1002\/14651858.CD000296.pub2-BIB87|cit87","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1093\/ajhp\/58.23.2229","article-title":"Oral budesonide approved for active Crohn's disease","volume":"58","author":"Thompson","year":"2001","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1572-0241.2002.05544.x","article-title":"Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life","volume":"97","author":"Thomsen","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub2-BIB89|cit89","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1155\/1997\/271653","article-title":"Budesonide in the management of patients with Crohn's disease","volume":"11","author":"Thomson","year":"1997","journal-title":"Can J Gastroenterol"},{"issue":"10","key":"10.1002\/14651858.CD000296.pub2-BIB90|cit90","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/j.1572-0241.1998.536_e.x","article-title":"Influence of topically and systemically active steroids on circulating leukocytes in Crohn's disease","volume":"93","author":"Tillinger","year":"1998","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB91|cit91","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1572-0241.2002.05593.x","article-title":"Treatment of Crohn's disease with budesonide: this rose still has thorns!","volume":"97","author":"Valentine","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"10.1002\/14651858.CD000296.pub2-BIB92|cit92","first-page":"1347","article-title":"[Pharmacotherapeutic compass 1998]","volume":"142","author":"Deventer","year":"1998","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"21","key":"10.1002\/14651858.CD000296.pub2-BIB93|cit93","first-page":"1191","article-title":"[Drug treatment of Crohn's disease]","volume":"142","author":"Deventer","year":"1998","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub2-BIB94|cit94","first-page":"A513","article-title":"[Therapy of chronic inflammatory intestinal disease]","volume":"21","author":"Gossum","year":"2000","journal-title":"Rev Med Brux"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB95|cit95","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2036.1995.tb00367.x","article-title":"Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease","volume":"9","author":"Ierssel","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB96|cit96","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0162-3109(95)00039-V","article-title":"Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn's disease","volume":"29","author":"Ierssel","year":"1995","journal-title":"Immunopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD000296.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0162-3109(96)00112-9","article-title":"Effect of cortisol and ACTH on corticosteroid-suppressed peripheral blood natural killer cells from healthy volunteers and patients with Crohn's disease","volume":"34","author":"Ierssel","year":"1996","journal-title":"Immunopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB98|cit98","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00054725-200005000-00017","article-title":"Budesonide: not for the long haul","volume":"6","author":"Varilek","year":"2000","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub2-BIB99|cit99","first-page":"352","article-title":"[Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection]","volume":"123","author":"Vermeire","year":"1998","journal-title":"Zentralbl Chir"},{"key":"10.1002\/14651858.CD000296.pub2-BIB100|cit100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2036.1997.tb00815.x","article-title":"Review article: Targeted drug delivery in treatment of intestinal diseases","volume":"11 Suppl 3","author":"Wikberg","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD000296.pub2-BIB101|cit101","unstructured":"Wolman SL Greenberg GR Gastroenterology 1991 A263"},{"issue":"25-26","key":"10.1002\/14651858.CD000296.pub2-BIB102|cit102","first-page":"1071","article-title":"[New therapeutic possibilities in chronic inflammatory bowel diseases]","volume":"86","author":"Zeitz","year":"1997","journal-title":"Schweiz Rundsch Med Prax"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0197-2456(81)90056-8","article-title":"A method for assessing the quality of a randomized control trial","volume":"2","author":"Chalmers","year":"1981","journal-title":"Control Clin Trials"},{"issue":"8","key":"10.1002\/14651858.CD000296.pub2-BIB104|cit104","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3109\/00365528708991947","article-title":"A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis","volume":"22","author":"Danielsson","year":"1987","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub2-BIB105|cit105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000296.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T19:58:56Z","timestamp":1706644736000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD000296.pub2"}},"subtitle":[],"editor":[{"given":"Anthony","family":"Otley","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2005,10,19]]},"references-count":105,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000296.pub2","relation":{},"subject":[],"published":{"date-parts":[[2005,10,19]]}}}